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Lymphotropic papovavirus (LPV) exhibits a highly restricted host range, in which only cells of primate
B-lymphocyte origin are permissive for infection. Its enhancer element contributes to this tropism, since
transcriptional potentiation is confined to cells of the hematopoietic lineage. Nuclear extracts from B and T
cells, but not from HeLa cells, contain protein factors that interact specifically with the LPV 63-base-pair
enhancer repeat, as demonstrated by DNase I footprinting and gel retardation experiments. Within the repeat
three sequence motifs were identified: the core motif, the Pu box, and a novel element named T motif.
Functional analysis demonstrated that these motifs as well as some sequences upstream of the repeat contribute
to the optimal activity of the enhancer. There are clear differences between the patterns of binding of the B and
T lymphocyte nuclear proteins to the enhancer which are also reflected in the transcriptional activity of the
enhancer in both cell types. Furthermore, the activity of the LPV enhancer and its interaction with nuclear
proteins seem to be regulated during B-cell differentiation.
Enhancers are cis-acting regulatory elements that poten-
tiate transcription in a relatively position- and orientation-
independent manner (for a review, see reference 17). One of
the best studied examples is the simian virus 40 (SV40)
enhancer (3, 19, 23, 47). It is located in the nontranscribed
regulatory region of the SV40 viral genome between the
early and late genes. Its major functional region consists of a
72-base-pair (bp) direct repeat, but approximately 120 bp
upstream of the repeat are also required for optimal en-
hancer activity (47). The whole enhancer region consists of a
variety of sequence motifs. Although most single motifs
cannot activate transcription to a considerable degree, oli-
gomerization of a motif can create powerful enhancers (11,
26, 33). Interestingly, these artificial enhancers have distinct
cell specificities. While an oligomer of the core sequence
shows almost the same pattern of activity as the entire
enhancer, an oligomer of the "pseudocore" is active only in
CV-1 cells and an oligomer of the Sph-I motif is lymphoid
cell specific (26, 33).
Enhancers have been characterized in a large number of
cellular genes as well (17). Besides being necessary for
appropriate levels of expression, in many cases they are also
responsible for tissue-specific expression of the correspond-
ing gene. The best-studied example of a tissue-specific
cellular enhancer is the immunoglobulin heavy-chain gene
enhancer, which is active only in B lymphocytes (2, 15, 25).
Like viral enhancers, cellular enhancers consist of different
sequence motifs (13). Techniques that can probe DNA-
protein interactions (e.g., DNase I footprinting, gel retarda-
tion, etc.) have shown that these motifs are the targets of
specific nuclear factors (17).
Lymphotropic papovavirus (LPV) belongs to the same
family of papovaviruses as do SV40, BK virus, and JC virus
(27, 37, 48). LPV infects only mature B lymphocytes from
primates (41). Its genome structure is almost identical to that
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of SV40; the genomes share about 80% homology in their
coding regions (28). The major regions of nonhomology are
confined to the sequences between the early and late tran-
scriptional start sites which, in LPV, as in SV40, encompass
an enhancer. The main feature of the LPV enhancer is a
63-bp direct repeat. In contrast to the SV40 enhancer, the
LPV enhancer is only active in cells of the hematopoietic
lineage and not in cells of fibroblastoid or epithelioid origin
(24). In this respect, the LPV enhancer activity is broader
than the infectivity of the virus itself. In accordance with the
in vivo results, it was shown that the LPV enhancer acti-
vates transcription in vitro when incubated with nuclear
extracts of B and T cells but not HeLa cells, a human cell
line of epithelial origin (35).
To explain the host range restriction of LPV and the cell
type specificity of the LPV enhancer, we found it necessary
first to characterize the cis-acting regulatory elements con-
tained within the enhancer and the trans-acting nuclear
proteins that recognize these sequences. Using DNase I
footprint analysis, we identified several sequence motifs
within the LPV enhancer which interact with nuclear factors
present in B and T lymphocytes. Mutational analysis of
these motifs demonstrated that they are crucial for enhancer
activity. Two of these regulatory elements interact with
nuclear factors from both B and T cells (30, 43). A newly
identified sequence motif is specifically protected in T cells.
Oligomerization of the area of the LPV enhancer which
contains the Pu box and the core sequences creates a
powerful cell-type-specific enhancer. Furthermore, both the
activity and the interaction of the LPV enhancer with
nuclear proteins are regulated during B-cell differentiation.
MATERIALS AND METHODS
Cell culture and extract preparation. HeLa cells were
grown in MEM Spinner medium (Flow Laboratories, Inc.)
with lx nonessential amino acids (GIBCO Laboratories); B-
and T-cell lines were grown in RPMI 1640 (GIBCO) with 3 g
of NaHCO3 per liter. The media were supplemented with 2
mM glutamine, 50 ,ug of streptomycin per ml, 50 IU of
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CELL-TYPE-SPECIFIC CONTROL ELEMENTS OF LPV ENHANCER
penicillin per ml, and 10% fetal calf serum. Nuclear extracts
were prepared as described before (6, 46), except that for
some extracts the nuclei were prepared by the addition of
0.05% Nonidet P-40 instead of mechanical disruption. No
difference in the binding pattern was observed in these
cases.
DNase I footprinting assays. The 234-bp HaeIII fragment of
LPV (see Fig. 1A) was excised, ligated to BglII linkers, and
cloned into the BamHI site of the SP65 polylinker such that
the LPV HaeIII site at position 158 was located near the
EcoRI site and the HaeIII site at position 392 was located
near the XbaI site of the polylinker. After restriction within
the polylinker, the plasmid was dephosphorylated and end
labeled, and the LPV enhancer fragment was subsequently
excised by a second restriction enzyme digestion. The
uniquely end-labeled fragment was used for DNase I foot-
printing assays and sequencing.
DNase I footprinting reactions were carried out essentially
as described previously (34, 45). Briefly, 8 ,ul of nuclear
extract (80 Rig) was preincubated for 20 min on ice with 28 ng
of pBR322 (restricted with HpaII) in a 10-pd volume contain-
ing 20 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid (HEPES) (pH 7.9), 20 mM KCl, 1 mM MgCl2, 2 mM
dithiothreitol, and 17% glycerol. After preincubation, 2 [lI of
the labeled template (104 cpm per reaction; approximately 3
fmol) was added and the samples were incubated for another
10 min on ice. The samples were heated to 20°C, and DNase
I (1 mg/ml; freshly diluted in 20% glycerol-1 mM MgCl2-20
mM KCl-1 mM dithiothreitol) was added for 90 s in different
amounts (1, 0.5, and 0.25 ,ug per reaction). Reactions were
terminated by the addition of 200 p,l of 0.2% sodium dodecyl
sulfate-30 ,g of tRNA per ml-0.6 M sodium acetate and
subsequent extraction with phenol-chloroform. After precip-
itation with isopropanol, the samples were analyzed on 5%
urea-polyacrylamide gels with a G-C sequence ladder run in
parallel. The control reactions, which contained no extract,
were treated as described for the samples except that the
DNase I concentrations used were 20 and 40 ng per reaction.
In every case, the procedure was carried out with two to four
independently prepared extracts.
Gel retardation assays. Oligonucleotides were end labeled
with polynucleotide kinase and purified by electrophoresis
on 10% polyacrylamide gels. Oligonucleotides (5,000 to
10,000 cpm; approximately 0.15 fmol) were incubated with 5
to 8 p.g of nuclear extract in a total volume of 20 pul of 10 mM
HEPES (pH 8.0)-5 mM MgCl2-50 mM KCl-1 mM spermi-
dine-0.5 mM dithiothreitol-17% glycerol-1 Lg of poly(dI-
dC) double-stranded heteropolymer (Boehringer Mannheim
Biochemicals) for 15 min at room temperature. DNA-protein
complexes were resolved on 5 to 6% polyacrylamide gels
(31). The gels were run for 3 to 4 h at 200 V, dried, and
exposed for 4 to 12 h to XAR film (Eastman Kodak Co.).
Cell transfections. Cells were transiently transfected with
the Gene Pulser electroporation apparatus (Bio-Rad Labo-
ratories) (5, 32). On the day before transfection, the cells
were split to a density of 3 x 105 cells per ml. On the next
day, 2 x 107 cells were collected by centrifugation, washed
once with phosphate-buffered saline, and suspended in 0.8
ml of phosphate-buffered saline. Supercoiled DNA (20 pug)
was added, and the cell suspension was pulsed at a voltage
setting of 250 to 400 V and a capacitance setting of 960 ,uF.
The average time constant was 12 to 14 ms. The cells were
kept for 10 min at room temperature and transferred to 50 ml
of medium. Approximately 48 h following transfection, cells
were harvested by centrifugation and washed first in 20 ml of
25 mM Tris hydrochloride (pH 7.5)-137 mM NaCl-5 mM
KCl-0.7 mM CaCI2-0.5 mM MgCl2-0.6 mM Na2HPO4 and
subsequently in 1 ml of 0.25 M Tris hydrochloride (pH 7.8).
The cells were suspended in 0.15 ml of 0.25 M Tris hydro-
chloride (pH 7.8) and sonicated. Cell debris was removed by
centrifugation, and the supernatant (extract) was assayed for
chloramphenicol acetyltransferase (CAT) activity (16). As-
say mixtures for CAT activity determinations contained 70
pI of extract, 0.2 ,Ci of ['4C]chloramphenicol (New England
Nuclear Corp.), 20 RI of 4 mM acetyl coenzyme A (Boehr-
inger), and 80 pl of 0.25 M Tris hydrochloride (pH 7.8).
Samples were incubated for 90 min at 37°C, extracted with
0.4 ml of ethyl acetate, dried under vacuum, and suspended
in 10 Ku of ethyl acetate. The acetylated forms of[14C]chloramphenicol were separated by thin-layer chroma-
tography.
Oligonucleotides. All oligonucleotides were synthesized
(BioSearch 8700 DNA synthesizer) with three guanidine or
cytidine residues at the ends to allow unidirectional ligation.
They were used either for gel retardation experiments or to
clone distinct parts of the LPV enhancer. For cloning, the
two corresponding single strands were heated together to
95°C and cooled down slowly to room temperature for
annealing. The double-stranded forms were separated from
single-stranded forms on 10% polyacrylamide gels, cut out,
and electroeluted in TE (10 mM Tris hydrochloride [pH 8], 1
mM EDTA [pH 8]) buffer. Subsequently, the oligonucleo-
tides were phosphorylated (polynucleotide kinase; Boehr-
inger), ligated to BglII linkers, and cloned into the BglII site
of p209A21 (16). For gel retardation experiments, [y-
32P]ATP (Amersham Corp.) was used for phosphorylation.
The double-stranded forms were isolated after separation
from free nucleotides and single-stranded forms on 10 to 15%
polyacrylamide gels.
RESULTS
Interaction of cell-type-specific factors with the LPV en-
hancer in vitro. Transient transfection experiments showed
FIG. 1. (A) Structure and position of the LPV enhancer. The LPV enhancer is situated in the noncoding region (700 bp) which separates
the early and late coding regions of the viral genome. Its position and orientation with respect to the early region are indicated. The HaeIII
fragment (positions 158 to 392) containing a 63-bp repeat was shown to act as an enhancer in vivo (24) and in vitro (35). The protected regions
in the DNase I footprint analysis are marked C, P, and T. ori, Origin of replication. (B) Comparison of protected regions in the DNase I
footprint assay of the LPV enhancer early strand with nuclear extracts from BJA-B, MOLT 4, and HeLa cells. The LPV enhancer fragment
was excised from the SP65 vector by restriction with EcoRI and XbaI. The strand coding for the viral early proteins was radioactively labeled
by a fill-in reaction with the Klenow polymerase. After incubation with the extracts, the labeled strand was treated with increasing amounts
of DNase 1 (0.25, 0.5, and 1.0 ,ug in lanes a, b, and c, respectively). In the control lanes (-prot.), DNA was incubated only with 20 to 40 ng
of DNase I. The digestion products were separated on 5% sequencing gels. Protected areas are marked C, P, and T. A, DNase
I-hypersensitive sites. The positions of the 63-bp repeats are indicated. (C) Summary of the results of the DNase I footprint analysis of the
LPV enhancer fragment in B- and T-cell nuclear extracts. The reactions for the late strand were carried out as described for the early strand
in panel B. L and E mark the late and early strands, respectively. A, DNase I-hypersensitive sites. The Pu box (P) and the core (C) sequences
are underscored, the protected regions (P, C, and T) are bracketed, and broken lines indicate weaker protection. The results are shown for
one repeat. In the second repeat the corresponding regions were protected (subscript 2). The numbering system is that of Pawlita et al. (28).
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that a 234-bp fragment including the LPV enhancer with the
63-bp repeat (Fig. 1A) was active in cells of the hematopoi-
etic lineage but not in epithelial cell lines (24). To identify
factors that interact with the LPV enhancer, we prepared
nuclear extracts from the human cell lines BJA-B, a Bur-
kitt's lymphoma cell line representing mature B lymphocytes
(20), MOLT 4, an acute T-cell lymphoblastic leukemia cell
line (22), and HeLa cells of epithelial origin (14) by previ-
ously described methods (6, 45) and used them in the DNase
I footprint analysis (12). The 234-bp fragment was radioac-
tively end labeled, incubated with the different nuclear
extracts, and partially digested with increasing concentra-
tions of DNase I.
Figure 1B shows the protected areas within the 63-bp
repeat on the strand coding for the early viral proteins. With
the BJA-B extracts, an 18-bp region containing the Pu box
(marked P) and the core motif (marked C) was protected in
both repeats. This region included a DNase I-hypersensitive
site consisting of two cytidine residues (motifs P and C; see
below). When the strand coding for the late viral proteins
was labeled, a region spanning 22 nucleotides was protected.
At the same position as in the strand coding for the early
proteins two DNase I-hypersensitive sites were observed
(data not shown). Incubation with the MOLT 4 extracts
resulted in a footprint in the same area (Fig. 1B), but the
protected sequence was more extended, indicating that a
modified factor or a different factor was binding in T cells. In
addition, a second protected region (marked T) of 16 nucle-
otides was found (Fig. 1B). In contrast to the results ob-
tained with the B- and T-cell extracts, no protected domains
could be seen in footprint experiments with HeLa nuclear
extracts (Fig. 1B). The same results were observed with
different extract preparations. The data from the DNase I
footprint analysis are summarized in Fig. 1C.
The protected region common to B and T cells contains
the core motif and the Pu box. The core motif is found in
many viral and cellular enhancers (43), and the Pu box, a
purine-rich region, is found in many lymphoid cell-specific
transcriptional elements, such as the immunoglobulin heavy-
chain gene enhancer (1), the 5' area of the major histocom-
patibility complex class II gene (7), and the SV40 enhancer
(30). In contrast to the core motif and the Pu box, the T motif
has not been described before.
Mutational analysis of the LPV enhancer in vitro. To
analyze the sequence requirements for the binding of the
nuclear factors in more detail, we synthesized and tested
several 39-bp oligonucleotides spanning the area of the Pu
box and the core motif in gel retardation assays with nuclear
extracts from BJA-B, MOLT 4, and HeLa cells (Fig. 2). The
oligonucleotide termed L 30 represents the wild-type se-
quence (Pu box and core), while L 31, L 32, L 33, and L 38
contain different introduced mutations. L 37 contains only
the Pu box wild-type sequence.
The wild-type oligonucleotide (L 30) formed a specific
complex with a nuclear protein present in BJA-B cells (lower
arrowhead in Fig. 2). The same complex was found with
nuclear extracts from the B-cell line Namalwa, a human
Burkitt's lymphoma cell line (data not shown). This factor
was present only in very small amounts in MOLT 4 and
HeLa extracts. On the other hand, the MOLT 4 extract
contained a different factor that formed a weak protein-DNA
complex and that was not seen with the other extracts (upper
arrowhead in Fig. 2). No specific complex could be detected
with HeLa nuclear extracts. The specificity of binding was
tested in competition experiments in which only the wild-
type oligonucleotide (L 30) competed effectively for binding
(data not shown). One band was detected with all oligonu-
cleotides (asterisk in Fig. 2) and was most likely due to
binding of a protein to three protruding guanosine or cytidine
residues which were introduced into all oligonucleotides to
facilitate unidirectional cloning (36). The amount of this
protein varied according to the conditions of cell growth and
nuclear extract preparation (see, for example, the two BJA-
B nuclear extracts in Fig. 2).
Two independent mutations in the Pu box region (L 31 and
L 38; Fig. 2) led to a dramatic decrease in the binding of the
B- and T-cell-specific factors, confirming the specificity of
the factors binding to the Pu box. Surprisingly, a mutation in
the core motif (L 32) had no effect on the binding of the
cell-specific factors. The altered G residue was previously
shown to be critical for the function of the core motif in the
SV40 enhancer (43). Simultaneous mutations in both the Pu
box and the core motif (L 33) resulted in a pattern similar to
the one observed with oligonucleotides L 31 and L 38, in
which only the Pu box was changed. These results demon-
strate that the Pu box sequences were sufficient for the
binding of the cell-type-specific factors seen in the gel
retardation assays. To confirm these results, we synthesized
a shorter oligonucleotide (L 37) containing the wild-type Pu
box but not the core motif. This oligonucleotide was suffi-
cient to form the B-cell-specific complex with BJA-B nuclear
extracts (Fig. 2).
In addition to the described complexes, faint protein-DNA
interactions were found with the L 30 wild-type oligonucle-
otide but were not further investigated. The introduction of
mutations into this oligonucleotide (L 31, L 32, L 33, and L
38) gave rise in some cases to new, faint complexes which
had mobilities different from those of the complexes elimi-
nated by the mutations. These complexes might have been
due to weak interactions with proteins that took place when
the specific factors did not bind or, alternatively, to the
creation of new binding sites.
An oligonucleotide spanning the T motif was also tested in
gel retardation assays. No specific complexes were formed
with any of the extracts, indicating that this sequence by
itself was not sufficient for binding (data not shown).
Characterization of the LPV enhancer in vivo. To test
whether the binding sites identified in vitro contributed to
the activity of the LPV enhancer in vivo, we introduced
deletions and specific mutations and cloned the correspond-
ing fragments in front of the SV40 promoter of plasmid
p209A21 driving the cat gene (21). The constructs were
introduced by electroporation into BJA-B, MOLT 4, and
HeLa cells. In all transfection experiments, the parental
vector p209A21 was used as a negative control and
pSV2CAT (16), which contains the SV40 enhancer, was
used as a positive control. Plasmid pLPV CATS (24), which
contains the entire LPV enhancer, was also used. In B and T
cells, all constructs were compared with pLPV CATS, the
activity of which was set arbitrarily at 100%. The different
constructs are shown in Fig. 3A.
As previously described, pLPV CATS is active in BJA-B
and MOLT 4 cells but not in HeLa cells (24). In HeLa cells,
activity was not detectable with any of the LPV enhancer
constructs, whereas the SV40 enhancer stimulated transcrip-
tion considerably (data not shown). The two 63-bp repeats
alone without further 5' or 3' sequences (pLPV 1) were
almost as active as the wild-type enhancer in MOLT 4 cells
(Fig. 3A). In BJA-B cells, the activity was reduced to 80%.
A single 63-bp repeat without any surrounding sequences
(pLPV 4) was not able to stimulate transcription in BJA-B
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FIG. 2. Comparison of the patterns of binding of nuclear extracts from BJA-B, MOLT 4, and HeLa cells to the Pu box-core region of the
LPV enhancer in gel retardation assays. The gel retardation assays were carried out as described in Materials and Methods. The sequences
of the synthetic double-stranded oligonucleotides spanning the Pu box and core sequences are shown. Mutated nucleotides in oligonucleotides
L 31, L 32, L 33, and L 38 are underlined. L 37 contains only Pu box sequences and was used to determine whether the Pu box itself is
sufficient to bind the B-cell-specific factor (rightmost two lanes). For the wild-type (wt) oligonucleotide L 30, the control (-protein) is shown
in Fig. 4, and the result for two independently prepared BJA-B extracts is shown here instead. The upper arrowhead indicates the
T-cell-specific protein-DNA complex, and the lower arrowhead indicates the B-cell-specific complex. The common band (asterisk) in all lanes
is due to nonspecific binding of a factor to the protruding ggg or ccc (corresponding strand) ends of the oligonucleotides. L 37 contains only
two c's.
4 cells. In contrast, one repeat plus 32 bp of upstream
sequences (pLPV 2) was active in BJA-B cells (30%) and
MOLT 4 cells (85%). Thus, the presence of two copies of the
repeat is necessary for full activity of the enhancer, but
upstream sequences contribute to the transcriptional stimu-
lation as well. The activity of the upstream sequences was
most pronounced in B cells, whereas in T cells the effect was
observed only when one of the repeats was present. The
same results were obtained independent of the orientation of
the inserted fragment.
Mutations in the Pu box (pLPV 3 and pLPV 6; same
mutations as in the L 38 oligonucleotide; see above) resulted
in a complete loss of activity in both BJA-B and MOLT 4
cells, confirming the importance of the Pu box for enhancer
activity in vivo. Mutations were introduced into the core and
T motifs in pLPV 4 (constructs pLPV 7 and pLPV 5,
respectively). Both constructs were inactive in MOLT 4
cells, demonstrating that both the T and the core motifs
contribute to enhancer activity in T cells.
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tissue specificity could be obtained by oligomerization of
certain sequence motifs (13, 26, 33). We were interested in
determining whether oligomerization of the area containing
the Pu box and core motif could result in an enhancer
element. The wild-type oligonucleotide L 30 (Pu box and
core) and the mutant oligonucleotide L 31 (mutated in the Pu
box) were oligomerized four times, inserted in p209A21
(constructs pLPV 8 and pLPV 9, respectively), and trans-
fected into BJA-B, MOLT 4, and HeLa cells. Both con-
structs were inactive in HeLa cells (data not shown). The
wild-type tetramer was a very strong enhancer in T cells but
was inactive in BJA-B cells. The mutated tetramer was only
30% as active as the wild-type tetramer in T cells. Surpris-
ingly, the mutated tetramer showed comparable activity in B
and T cells (Fig. 3A).
LPV enhancer activity during B-lymphocyte differentiation.
B lymphocytes follow a precise program of differentiation.
In pre-B cells, only immunoglobulin ,. heavy-chain genes are
expressed. In later stages, transcription of the K or X light
chains follows and immunoglobulin M molecules appear on
the surface of virgin B,] cells. These cells give rise first to
mature B, +, cells and, following antigen stimulation, to
blast and plasma cells (4).
The transcriptional factor NF-KB, involved in the expres-
sion of the immunoglobulin genes, is only present in mature
B cells, whereas the factor OTF-2 is also present in earlier
stages (34, 38-41, 44). Since it has been demonstrated that
sequences homologous to the Pu box are also present in the
immunoglobulin heavy-chain enhancer and are required for
activity (30), we were interested in determining whether the
LPV enhancer is regulated during B-cell differentiation and
whether the activity correlates with the presence of the
corresponding nuclear factors. To answer the first question,
we transfected several cell lines representing different stages
of B-lymphocyte differentiation with plasmids pLPV CAT,
and pSV2CAT (as a control). The activity in all cell lines was
compared with the activity of pSV2CAT in BJA-B cells,
which was set at 100. The SV40 enhancer strongly stimu-
lated transcription in all cell lines, whereas the LPV en-
hancer was only active in mature B cells (BJA-B and Daudi)
as well as in the plasma cell line R-LICR (Table 1). In these
three cell lines, the activity of the LPV enhancer was
significantly lower compared with that of the SV40 enhancer,
but the ratio of SV40 to LPV enhancer activity was constant.
In pre-B cells (cell lines 207 and 697) or in cells in an early
stage of differentiation (LBW 4) (8, 10, 18), the LPV en-
hancer was not active.
Subsequently, nuclear extracts from BJA-B cells (repre-
senting mature B cells) and 207 cells (representing pre-B
cells) were compared in gel retardation assays. The B-
cell-specific factor binding to the Pu box (arrowhead in Fig.
4) was much more abundant in the mature B-cell line BJA-B.
The pre-B cell line 207 contained only low levels of the
factor. As a control, an oligonucleotide containing the XP-




p209A21 pSV2CAT pLPV CAT,
207 1 50 1
697 1 57 1
LBW 4 1 67 1
BJA-B 2 100 51
Daudi 1 60 30
R-LICR 1 43 20
a Cell lines in different stages of B-lymphocyte differentiation were trans-
fected with plasmid pLPV CAT,. Cell lines 207 and 697 are pre-B cells. LBW
4 is a cell line in an early stage of differentiation, while Daudi and BJA-B
represent mature B cells. R-LICR is a plasma cell line. p209A21 and
pSV2CAT wre transfected in parallel as controls. The activity of pSV2CAT in
BJA-B cells was set at 100, corresponding to 85% CAT conversion (for
details, see Materials and Methods).
1-binding site of the immunoglobulin ,. heavy-chain gene
enhancer was used in these experiments (9). This oligonu-
cleotide detected equal amounts of the corresponding factors
in both cell lines, indicating that the difference observed was
specific for the Pu box-binding protein.
DISCUSSION
LPV represents an ideal system for studying cell-type-
specific gene expression. Its enhancer, a 234-bp fragment
containing a direct repeat of 63 bp, is active only in cells of
the hematopoietic lineage of primates (24). The aim of this
study was to identify and characterize the cis-acting ele-
ments and their corresponding trans-acting factors that are
responsible for this tissue specificity and to compare the
requirements for enhancer activity in B and T lymphocytes.
The results presented here demonstrate that three sequence
elements, namely, the core, the Pu box, and the T motif,
bind nuclear proteins present only in lymphoid cells. Muta-
tional analysis showed that these motifs all contribute to
enhancer activity. Besides the two 63-bp repeats which
contain these three transcriptional elements, sequences out-
side the repeats also contribute to optimal enhancer activity.
Thus, the LPV enhancer, like most transcriptional elements,
consists of different sequence motifs. Since it is composed of
only a small number of motifs which are active only in
lymphoid cells, it is not surprising that the activity of the
whole enhancer is also restricted to these cells. In contrast to
this very specific enhancer, the SV40 enhancer is highly
active in a variety of cell types. In this case, many motifs,
such as the core, the pseudocore, the Sph-I motif, the
octamer, the Pu box, and the P motif, contribute in various
extents to enhancer activity (19, 26).
The three motifs protected in the footprint analysis of the
LPV enhancer are the Pu box, the core, and the T motif. The
FIG. 3. (A) Functional analysis of the LPV enhancer by the CAT assay. For all transfection experiments, 20 p.g of supercoiled DNA was
used. The DNA was introduced into the cells by electroporation, and 48 h after transfection the CAT extracts were prepared (for details, see
Materials and Methods). The CAT activity of the LPV enhancer (pLPV CATJ) was set in all cell lines at 100%. pSV2 CAT and p209A21 were
used as positive and negative controls, respectively. On the left side of the panel, the LPV constructs used for transfection are shown. The
three motifs, T motif (T), Pu box (P), and core motif (C), are indicated. Asterisks indicate mutated sequences. On the right side of the panel,
the CAT activities of the different constructs (as percentages) are compared with that of pLPV CAT,. pLPV CAT5 represents the wild-type
enhancer, pLPV 1 contains the two 63-bp wild-type repeats without any surrounding sequences, pLPV 8 is a tetramer of oligonucleotide L
30, and pLPV 9 is a tetramer of oligonucleotide L 31 (Fig. 2). The subscripts "s" and "as" refer to sense and antisense, respectively. (B)
Sequences of the LPV CAT constructs used for transfection in BJA-B, MOLT 4, and HeLa cells. pLPV 2 and pLPV 4 contain only wild-type
sequences. In the other constructs, the introduced mutations are underlined. All constructs were made with synthetic oligonucleotides. The
brackets indicate the protected areas in the DNase I footprint analysis (Fig. 1B and C).
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FIG. 4. Binding of nuclear factors to the Pu box-core region of
the LPV enhancer in the pre-B cell line 207 and the mature B-cell
line BJA-B. The sequence of oligonucleotide L 30 is given in Fig. 2.
In the leftmost lanes of each panel the oligonucleotide was incubated
without extract. 207 is a pre-B cell line, and BJA-B is a mature B-cell
line. The arrowhead indicates the B-cell-specific complex formed
with Pu box sequences. The XP-1-binding site of the immunoglob-
ulin ,. heavy-chain gene enhancer was incubated with the same
extracts as a control.
Pu box is found in a large number of lymphoid cell-specific
transcriptional elements, such as the major histocompatibil-
ity complex class II genes and the immunoglobulin enhancer
(1, 7). It was first identified in the SV40 enhancer, in which
it is found approximately 120 bp upstream of the 72-bp
repeats. Duplication of a DNA segment containing the Pu
box creates a lymphoid cell-specific enhancer (30). In the
case of LPV, oligomerization of the Pu box-core sequence
also creates a cell-type-specific enhancer but, in contrast to
that in SV40, it is active only in T cells. As the DNase I
footprinting and gel retardation experiments showed, dif-
ferent factors are bound in B and T lymphocytes. It has been
shown for the octamer motif that the same sequence binds a
plethora of factors which can, in turn, mediate different
tissue specificities (36). Recently, a 100-kilodalton protein
from mouse lymphocytes that interacted with sequences
similar to the Pu box and present in the immunoglobulin CR
enhancer was purified and shown to mediate immunoglobu-
lin enhancer activity (1); however, it is unclear whether this
factor binds the LPV Pu box. As the in vivo experiments
demonstrated, the Pu box is essential for B- and T-cell
activity, although the oligomer works only in T cells. Muta-
tions in the Pu box lead to a dramatic decrease in activity in
both cell types. So, although the Pu box is required for
activity in B cells, it probably requires other sequences for
its activity. If these sequences are not present, the binding of
the factor might be inhibitory.
The Pu box factor seems to be regulated during B-cell
differentiation. Strong binding activity is detected in mature
B cells but not in pre-B cells. In this respect, the Pu
box-binding protein resembles nuclear factor NF-KB, which
is induced in mature B cells (38, 42), and not OTF-2, which
is also present in pre-B cells. It is not yet clear whether the
Pu box-binding factor can be induced in other cell types, like
NF-KB can (38). The LPV enhancer is only active in B cells,
such as BJA-B, that show strong binding of the factor,
providing additional evidence that the Pu box is a crucial
element for transcriptional activity. It will be interesting to
see if the Pu box interacts with proteins of other cells of the
hematopoietic lineage. Moreover, it will be interesting to see
if oligomerized L 30 is active in these cells or if its activity is
restricted to T lymphocytes.
The core motif is found in many transcriptional elements,
and oligomers of the core motif are active in a wide variety
of cells (26). However, the core motif found in the LPV
enhancer binds lymphoid cell-specific proteins since, in
contrast to the results with nuclear extracts of lymphoid
cells, it is not protected in the DNase I footprint analysis
with HeLa extracts. In addition, an oligomer of the mutated
oligonucleotide L 31, which contains a tetramer of the
wild-type core sequence, is active in B and T cells but not in
HeLa cells. Interestingly, the LPV core is identical to the
core in the immunoglobulin enhancer, and mutational anal-
ysis showed that the core contributes to immunoglobulin
enhancer activity (29). It is noteworthy that in the immuno-
globulin C,u enhancer the Pu box and the core motif are also
found in close proximity and the core represents the strong-
est homology between these two lymphoid cell-specific
elements (34).
Although the core motif is clearly protected in the foot-
printing experiments, an oligonucleotide consisting only of
the core sequence does not bind proteins in the gel retarda-
tion experiments. It is probable that the core-binding protein
needs additional sequences not present in the oligonucleo-
tide and/or that the binding of proteins outside the core
sequence is required. This might also be true for the T motif:
the same sequence which is protected in the DNase I
footprinting experiments with T-cell nuclear extracts does
not form a complex with nuclear proteins in the gel retarda-
tion assays. Mutational analysis proved that this sequence,
like the Pu box and the core motif, contributes to enhancer
activity in T lymphocytes. However, computer analysis
shows that no sequence homologous to the T motif has been
described to date in any regulatory element.
Thus, all three motifs identified in the 63-bp repeats of the
LPV enhancer by in vitro experiments are involved in
mediating transcriptional activity in a cell-type-specific man-
ner. In addition, sequences upstream of the repeats contrib-
ute to the overall activity. The results presented here de-
scribe the activity of the LPV enhancer in B and T cells.
Since the LPV enhancer is also active in other cell types of
the hematopoietic lineage, such as erythrocytes, macro-
phages, and granulocytes (24), further insights into its activ-
ity should come from characterizing cis-acting elements and
the corresponding trans-acting factors present in these cells
and comparing them with the ones analyzed in B and T
lymphocytes. Moreover, purification and cloning of the
proteins interacting with the LPV enhancer and regulating its
activity will help to better understand its cell type specificity
and regulation of transcription in cells of the hematopoietic
lineage.
ACKNOWLEDGMENTS
The first two authors contributed equally to this work.
We thank Steven R. Bauer for providing several mouse and













 January 4, 2017 by M







CELL-TYPE-SPECIFIC CONTROL ELEMENTS OF LPV ENHANCER
work, H.-P. Geithe for synthesis of oligonucleotides, and G.
Dressler, M. Goulding, A. Puischel, and H. Scholer for helpful
comments on the manuscript.
J.R.E. and B.J. were supported by the Max-Planck Society.
A.K.H. was a recipient of a postdoctoral fellowship from the
European Molecular Biology Organization. This work was sup-
ported by Bundesministerium fur Forschung und Technologie.
LITERATURE CITED
1. Araki, K., H. Maeda, J. Wang, D. Kitamura, and T. Watanabe.
1988. Purification of nuclear trans-acting factor involved in the
regulated transcription of a human immunoglobulin heavy chain
gene. Cell 53:723-730.
2. Banerji, J., L. Olson, and W. Schaffner. 1983. A lymphocyte-
specific cellular enhancer is located downstream of the joining
region in immunoglobulin heavy chain genes. Cell 33:729-749.
3. Banerji, J., S. Rusconi, and W. Schaffner. 1981. Expression of a
P-globin gene is enhanced by remote SV 40 DNA sequences.
Cell 27:299-308.
4. Blackwell, T. K., and F. W. Alt. 1988. Immunoglobulin genes, p.
1-60. In B. D. Hames and D. M. Glover (ed.), Frontiers in
molecular biology. Molecular immunology. IRL Press Ltd.,
Washington, D.C.
5. Chu, G., H. Hayakawa, and P. Berg. 1987. Electroporation for
the efficient transfection of mammalian cells with DNA. Nucleic
Acids Res. 15:1311-1326.
6. Dignam, J. D., R. M. Lebovitz, and G. Roeder. 1983. Accurate
transcription initiation by RNA polymerase II in a soluble
extract from isolated mammalian nuclei. Nucleic Acids Res.
11:1475-1489.
7. Dorn, A., H. J. Fehling, W. Koch, M. Le Meur, P. Gerlinger, C.
Benoist, and D. Mathis. 1988. B-cell control region at the 5' end
of a major histocompatibility complex class II gene: sequences
and factors. Mol. Cell. Biol. 8:3975-3987.
8. Edwards, P. A. W. 1981. Some properties and applications of
monoclonal antibodies. Biochem. J. 200:1-10.
9. Ephrussi, A., G. M. Church, S. Tonegawa, and W. Gilbert. 1985.
B lineage-specific interaction of an immunoglobulin enhancer
with cellular factors in vivo. Science 227:134-140.
10. Findley, H. W., Jr., M. D. Cooper, T. H. Kim, C. Alvarado, and
A. H. Ragab. 1982. Two new acute lymphoblastic leukemia cell
lines with early B-cell phenotypes. Blood 60:1305-1309.
11. Fromental, C., M. Kanno, H. Nomiyama, and P. Chambon.
1988. Cooperativity and hierarchical levels of functional orga-
nization in the SV 40 enhancer. Cell 54:943-953.
12. Galas, D., and A. Schmitz. 1978. DNase I footprinting: a simple
method for the detection of protein-DNA binding specificity.
Nucleic Acids Res. 5:3157-3170.
13. Gerster, T., P. Matthias, M. Thali, J. Jiricny, and W. Schaffner.
1987. Cell type-specificity elements of the immunoglobulin
heavy chain gene enhancer. EMBO J. 6:1323-1329.
14. Gey, G. O., W. D. Coffman, and M. K. Kubicek. 1952. Tissue
culture studies of the proliferative capacity of cervical carci-
noma and normal epithelium. Cancer Res. 12:264-265.
15. Gillies, S. D., S. L. Morrison, V. T. Oi, and S. Tonegawa. 1983.
A tissue-specific transcription enhancer element is located in the
major intron of a rearranged immunoglobulin heavy chain gene.
Cell 33:717-728.
16. Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982.
Recombinant genomes which express chloramphenicol acetyl-
transferase in mammalian cells. Mol. Cell. Biol. 2:1044-1051.
17. Hatzopoulos, A. K., U. Schlokat, and P. Gruss. 1988. Enhancers
and other cis-acting regulatory elements, p. 43-96. In B. D.
Hames and D. M. Glover (ed.), Frontiers in molecular biology.
Transcription and splicing. IRL Press Ltd., Washington, D.C.
18. Hendershot, I., and D. Levitt. 1982. Differential regulation of
membrane and secretory 1L chain synthesis in human B cell
lines. J. Exp. Med. 156:1622-1634.
19. Herr, W., and J. Clarke. 1986. The SV 40 enhancer is composed
of multiple functional elements that can compensate for one
another. Cell 45:461-470.
20. Klein, G., B. Giovanella, A. Westman, J. S. Stehlin, and D.
Munford. 1975. An EBV-genome-negative cell line established
from an American Burkitt lymphoma; receptor characteristics,
EBV infectibility and permanent conversion into EBV-positive
sublines by in vitro infection. Intervirology 5:319-334.
21. Laimins, L. A., G. Khoury, C. Gorman, B. Howard, and P.
Gruss. 1982. Host-specific activation of transcription by tandem
repeats from simian virus 40 and Moloney murine sarcoma
virus. Proc. Natl. Acad. Sci. USA 79:6453-6457.
22. Minowada, J., T. Ohnura, and G. E. Moore. 1972. Rosette-
forming human lymphoid-cell lines. I. Establishment and evi-
dence for origin of thymus-derived lymphocytes. J. Natl. Can-
cer Inst. 49:891-895.
23. Moreau, P., R. Hen, B. Wasylyk, R. Everett, M. P. Gaub, and P.
Chambon. 1981. The SV 40 72 bp repeat has a striking effect on
gene expression both in SV 40 and other chimeric recombinants.
Nucleic Acids Res. 9:6047-6068.
24. Mosthaf, L., M. Pawlita, and P. Gruss. 1985. A viral enhancer
element specifically active in human haematopoietic cells. Na-
ture (London) 315:597-600.
25. Neuberger, M. S. 1983. Expression and regulation of immuno-
globulin heavy chain gene transfected into lymphoid cells.
EMBO J. 2:1373-1378.
26. Ondek, B., A. Shepard, and W. Herr. 1987. Discrete elements
within the SV 40 enhancer region display different cell-specific
activities. EMBO J. 6:1017-1025.
27. Padgett, B. L., C. M. Rogers, and D. L. Walker. 1977. JC virus,
a human polyomavirus associated with progressive multifocal
leukoencephalopathy: additional biological characteristics and
antigenic relationships. Infect. Immun. 15:656-662.
28. Pawlita, M., A. Clad, and H. zur Hausen. 1985. Complete DNA
sequence of lymphotropic papovavirus: prototype of a new
species of the polyomavirus genus. Virology 143:196-211.
29. Perez-Mutul, J., M. Macchi, and B. Wasylyk. 1988. Mutational
analysis of the contribution of sequence motifs within the Ig
enhancer to tissue specific transcriptional activation. Nucleic
Acids Res. 16:6085-6096.
30. Petterson, M., and W. Schaffner. 1987. A purine-rich DNA
sequence motif present in SV 40 and lymphotropic papovavirus
binds a lymphoid-specific factor and contributes to enhancer
activity in lymphoid cells. Genes Dev. 1:962-972.
31. Piette, J., M. H. Krysze, and M. Yaniv. 1985. Specific interac-
tion of cellular factors with the B enhancer of polyomavirus.
EMBO J. 4:2675-2685.
32. Potter, H., L. Weir, and P. Leder. 1984. Enhancer-dependent
expression of human K immunoglobulin genes introduced into
mouse pre-B lymphocytes by electroporation. Proc. Natl. Acad.
Sci. USA 81:7161-7165.
33. Schirm, S., J. Jiricny, and W. Schaffner. 1987. The SV 40
enhancer can be dissected into multiple segments, each with a
different cell specificity. Genes Dev. 1:65-74.
34. Schlokat, U., D. Bohmann, H. Scholer, and P. Gruss. 1986.
Nuclear factors binding specific sequences within the immuno-
globulin enhancer interact differentially with other enhancer
elements. EMBO J. 5:3251-3256.
35. Scholer, H. R., and P. Gruss. 1985. Cell type-specific transcrip-
tional enhancement in vitro requires the presence of trans-acting
factors. EMBO J. 4:3005-3013.
36. Scholer, H. R., A. K. Hatzopoulos, R. Balling, N. Suzuki, and P.
Gruss. 1989. A family of octamer-specific proteins present
during mouse embryogenesis: evidence for germline-specific
expression of an Oct factor. EMBO J. 8:2543-2550.
37. Seif, I., G. Khoury, and R. Dhar. 1979. The genome of human
papovavirus BKV. Cell 18:963-977.
38. Sen, R., and D. Baltimore. 1986. Inducibility of K immunoglob-
ulin enhancer binding protein NF-KB by a posttranslational
mechanism. Cell 47:921-928.
39. Singh, H., R. Sen, D. Baltimore, and P. A. Sharp. 1986. A
nuclear factor that binds a conserved sequence motif in tran-
scriptional control elements of immunoglobulin genes. Nature
(London) 319:154-157.
40. Staudt, L. M., H. Singh, R. Sen, T. Wirth, P. A. Sharp, and D.
Baltimore. 1986. A lymphoid specific protein binding to the





 January 4, 2017 by M







1666 ERSELIUS ET AL.
41. Takemoto, K. K., A. Furuno, K. Kato, and K. Yoshiike. 1982.
Biological and biochemical studies of African green monkey
lymphotropic papovavirus. J. Virol. 42:502-509.
42. Wall, R., M. Briskin, C. Carter, H. Goven, A. Taylor, and P.
Kincade. 1986. A labile inhibitor blocks immunoglobulin K light
chain gene transcription in pre-B leukemic cell line. Proc. Natl.
Acad. Sci. USA 83:295-298.
43. Weiher, H., M. Konig, and P. Gruss. 1983. Multiple point
mutations affecting the simian virus 40 enhancer. Science 219:
626-631.
44. Weinberger, J., D. Baltimore, and P. A. Sharp. 1986. Distinct
factors bind to apparently homologous sequences in the immu-
noglobulin heavy chain enhancer. Nature (London) 322:846-
848.
45. Wildeman, A., P. Sassone-Corsi, T. Grundstrom, M. Zenke, and
P. Chambon. 1984. Stimulation of in vitro transcription from the
SV 40 early promoter by the enhancer involves a specific
trans-acting factor. EMBO J. 13:3129-3133.
46. Wildeman, A. G., M. Zenke, C. Schatz, M. Wintzerith, T.
Grundstrom, H. Matthes, K. Takahashi, and P. Chambon. 1986.
Specific protein binding to the simian virus 40 enhancer in vitro.
Mol. Cell. Biol. 6:2098-2105.
47. Zenke, M., T. Grundstrom, H. Matthes, M. Wintzerith, C.
Schatz, A. Wildeman, and P. Chambon. 1986. Multiple sequence
motifs are involved in SV 40 enhancer function. EMBO J.
5:387-397.
48. zur Hausen, H., and L. Gissmann. 1979. Lymphotropic papova-
viruses isolated from African green monkey and human cells.




 January 4, 2017 by M
AX PLANCK INST F BIO
PHY CHEM
http://jvi.asm.org/
D
ow
nloaded from
 
